 |
|
|
| |
PRIOR THERAPY WITH SOFOSBUVIR/VELPATASVIR ASSOCIATED
WITH REDUCED RESPONSE TO SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR:
RESULTS FROM A CANADIAN PROSPECTIVE REGISTRY
|
| |
| |
AASLD 2019 Nov 8-12 Boston
Reported by Jules Levin
Fernanda de Quadros Onofrio1, Dr. Curtis Cooper2, Dr. Sergio Marcelo Borgia3, Dr. Marie-Louise Claire Vachon4, Dr. Alnoor Ramji5, Les Lilly6, Dr. Alexander Wong7, Joshua Booth1, Izza Sattar8, Heidy Morales9, Dr. Samuel S. Lee10, Dr. Brian Conway11 and Jordan J. Feld, MD, MPH, FAASLD12, (1)Toronto Centre for Liver Disease, UHN, (2)University of Ottawa, (3)William Osler Health Centre, (4)Centre Hospitalier Universitaire de Quacbec, (5)Medicine, University of British Columbia, (6)Multiorgan Transplant Program, University Health Network (Toronto General Hospital), (7)Department of Medicine, University of Saskatchewan, (8)Hepatology, UHN, (9)Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, (10)Medicine, University of Calgary, (11)Vancouver Infectious Diseases Centre, (12)Toronto Centre for Liver Disease, University of Toronto University Health Network
|
| |
|
|
|
|
|
